Document:

Commitment Letter

 Exhibit 10.2 

 

 

 April 7, 2011 
 Sunrise Senior Living, Inc. 
 7902 Westpark Drive 

McLean, VA 22102 
 Attention: Edward W. Burnett

 Re:         Proposed $65,000,000.00 Senior Revolving Credit Facility to Sunrise
Senior Living, Inc. 
 Ladies and Gentlemen: 
 Sunrise Senior Living, Inc. (“Borrower”) has requested that KeyBank Capital Markets, Inc. (“KBCM”), agree to structure, arrange and syndicate a senior revolving credit
facility in an aggregate amount of up to $65,000,000.00 (the “Facility”), and that KeyBank National Association (“KeyBank”) commit to provide a portion of the Facility and to serve as administrative agent for the
Facility. KBCM is pleased to advise you that it is willing to act as exclusive arranger for the Facility. 
 Furthermore,
KeyBank and KBCM are pleased to advise you of (a) KeyBank’s commitment to provide up to $50,000,000.00 of the Facility, and (b) KBCM’s agreement to use commercially reasonable efforts to assemble a syndicate of financial
institutions identified by KBCM in consultation with you, to provide the balance of the necessary commitments for the Facility, in each case upon the terms and subject to the conditions set forth or referred to in this commitment letter (the
“Commitment Letter”) and in the Term Sheet attached hereto as Exhibit A (the “Term Sheet”). In the event the Facility cannot be successfully syndicated under the terms outlined in the Term Sheet, the Borrower
agrees that the KeyBank and KBCM shall be entitled with the consent of the Borrower and any guarantors (which shall not be unreasonably withheld, conditioned or delayed), to change the structure or terms of the Facility, if the KeyBank and KBCM
determine that such changes are advisable in order to ensure a successful syndication. The Term Sheet shall be deemed to be amended to reflect such changes and the syndication process shall continue. For purposes hereof, a successful syndication is
one in which commitments (in compliance with the terms of the Term Sheet) totaling in an amount equal to the Facility (including a reduction of Key Bank’s portion of the Facility to its desired hold level of not greater than $50,000,000) have
been received from financial institutions acceptable to the KBCM and Borrower. 
 It is agreed that KeyBank
will act as the sole and exclusive administrative agent, and that KBCM will act as the sole and exclusive Lead Arranger and Bookrunner (in such capacities, the “Lead Arranger”) for the Facility; provided that the Borrower
acknowledges and agrees that the commitments of KeyBank to act as administrative agent and to provide a portion of the Facility may be assumed by an affiliated bank and KBCM may assign some or all of its rights and delegate some or all of its
responsibilities hereunder to one of its affiliates. You agree that no other agents, co-agents or arrangers will be appointed, no other titles will be awarded and no compensation (other that that expressly contemplated by the Term Sheet) will be
paid in connection with the Facility unless you and we shall so agree. 

 We intend to syndicate the Facility [(including, in our discretion, all or part of
KeyBank’s commitment hereunder)] to a group of financial institutions (together with KeyBank, the “Lenders”) identified by us in consultation with you. KBCM intends to commence syndication efforts promptly upon the execution of
this Commitment Letter, and you agree actively to assist KBCM in completing a syndication satisfactory to it. Such assistance shall include (a) your using commercially reasonable efforts to ensure that the syndication efforts benefit materially
from your existing lending relationships, (b) direct contact between senior management and advisors of the Borrower and the proposed Lenders, (c) the hosting, with KBCM, of one or more meetings of prospective Lenders and (d) as set
forth in the next paragraph, assistance in the preparation of materials to be used in connection with the syndication (collectively with the Term Sheet, the “Information Materials”). 

You will assist us in preparing Information Materials, including a Confidential Information Memorandum, for distribution to prospective
Lenders. Before distribution of any Information Materials, you agree to execute and deliver to us a letter in which you authorize distribution of the Information Materials to a prospective Lender’s employees. 

As the Lead Arranger, KBCM will manage all aspects of the syndication, including decisions as to the selection of institutions to be
approached and when they will be approached, when their commitments will be accepted, which institutions will participate, the allocations of the commitments among the Lenders (as defined below) and the amount and distribution of fees among the
Lenders. In acting as the Lead Arranger, KBCM will have no responsibility other than to arrange the syndication as set forth herein and shall in no event be subject to any fiduciary or other implied duties. Additionally, the Borrower acknowledges
and agrees that, as Lead Arranger, KBCM is not advising the Borrower as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Borrower shall consult with its own advisors concerning such matters and shall be
responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and KBCM shall have no responsibility or liability to the Borrower with respect thereto. Any review by KBCM of the Borrower, the
transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of KBCM and shall not be on behalf of the Borrower. 
 To assist KBCM in its syndication efforts, you agree promptly to prepare and provide to KBCM and KeyBank all information with respect to the Borrower and the transactions contemplated hereby, including
all financial information and projections (the “Projections”), as we may reasonably request in connection with the arrangement and syndication of the Facility. You hereby represent and covenant that (a) all information other
than the Projections (the “Information”) that has been or will be made available to KeyBank or KBCM by you, the Borrower or any of your representatives is or will be, when furnished, complete and correct in all material respects and
does not or will not, when furnished, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not materially misleading in light of the circumstances under which
such statements are made and (b) the Projections that have been or will be made available to KeyBank or KBCM by you, the Borrower or any of your representatives have been or will be prepared in good faith based upon reasonable assumptions. You
understand that in arranging and syndicating the Facility we may use and rely on the Information and Projections without independent verification thereof. 

  
 -2-

 As consideration for KeyBank’s commitment hereunder and KBCM’s agreement to
perform the services described herein, you. agree to pay to KeyBank the nonrefundable fees set forth in the Term Sheet. 

KeyBank’s commitment hereunder and KBCM’s agreement to perform the services described herein are subject to (a) there not
occurring or becoming known to us any material adverse condition or material adverse change in or affecting the business, operations, property, condition (financial or otherwise) or prospects of the Borrower and its subsidiaries, taken as a whole,
(b) our not becoming aware after the date hereof of any information or other matter affecting the Borrower or the transactions contemplated hereby which is inconsistent in a material and adverse manner with any such information or other matter
disclosed to us prior to the date hereof, (c) our satisfaction that prior to and during the syndication of the Facility there shall be no competing offering, placement or arrangement of any debt securities or bank financing by or on behalf of
the Borrower or any affiliate thereof, except for the $100 million junior subordinated convertible note offering that Borrower is planning during the week of April 11, 2011, (d) the negotiation, execution and delivery on or before May 15,
2011 of definitive documentation with respect to the Facility satisfactory to KeyBank and its counsel, (e) your compliance with the terms of this Commitment Letter (including any flex pricing provisions set forth thereunder) and (f) the
other conditions set forth or referred to in the Term Sheet. The terms and conditions of KeyBank’s commitment hereunder and of the Facility are not limited to those set forth herein and in the Term Sheet. Those matters that are not covered by
the provisions hereof and of the Term Sheet are subject to the approval and agreement of KeyBank, KBCM and the Borrower. 
 You
agree (a) to indemnify and hold harmless KeyBank, KBCM and their affiliates and their respective officers, director employees, advisors, and agents (each, an “indemnified person”) from and against any and all losses, claims,
damages and liabilities to which any such indemnified person may become subject arising out of or in connection with this Commitment Letter, the Facility, the use of the proceeds thereof or any related transaction or any claim, litigation,
investigation or proceeding relating to any of the foregoing, regardless of whether any indemnified person is a party thereto, and to reimburse each indemnified person upon demand for any legal or other expenses incurred in connection with
investigating or defending any of the foregoing, provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities or related expenses to the extent they are found by a final, non-appealable
judgment of a court to arise from the willful misconduct or gross negligence of such indemnified person, and (b) to reimburse KeyBank, KBCM and their affiliates on demand for all out-of-pocket expenses (including due diligence expenses,
syndication expenses, consultant’s fees and expenses (if any), travel expenses, and reasonable fees, charges and disbursements of counsel) incurred in connection with the Facility and any related documentation (including this Commitment Letter,
the Term Sheet and the definitive financing documentation) or the administration, amendment, modification or waiver thereof. No indemnified person shall be liable for any indirect or consequential damages in connection with its activities related to
the Facility. No indemnified person shall be liable for any damages arising from the use by others of Information or other materials obtained through electronic, telecommunications or other information transmission systems or for any special,
indirect, consequential or punitive damages in connection with the Facility. If you have already paid a deposit to KeyBank pursuant to the terms of a proposal letter or other written agreement (the

  
 -3-

 
“Deposit”), and the Facility is consummated, the Deposit less all expenses incurred will be applied at closing toward any other closing fees and expenses. If the Facility is not
consummated for any reason whatsoever, KeyBank will be entitled to retain all unused portions of the Deposit 
 This Commitment
Letter shall not be assignable by you without the prior written consent of KeyBank and KBCM (and any purported assignment without such consent shall be null and void), is intended to be solely for the benefit of the parties hereto and is not
intended to confer any benefits upon, or create any rights in favor of, any person other than the parties hereto. This Commitment Letter may not be amended or waived except by an instrument in writing signed by you, KeyBank and KBCM. This Commitment
Letter may be executed in any number of counterparts, each of which shall be an original, and all of which, when taken together, shall constitute one agreement. Delivery of an executed signature page of this Commitment Letter by facsimile
transmission shall be effective as delivery of a manually executed counterpart hereof. This Commitment Letter and the Term Sheet set forth the entire understanding of the parties with respect thereto. This Commitment Letter shall be governed by, and
construed in accordance with, the laws of the State of New York. The Borrower consents to the nonexclusive jurisdiction and venue of the state or federal courts located in the City of New York. EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, (A) ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS COMMITMENT LETTER, THE TERM SHEET OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON
CONTRACT, TORT OR ANY OTHER THEORY) AND (B) ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LEGAL PROCEEDING IN THE STATE OR FEDERAL COURTS LOCATED IN THE CITY OF NEW YORK. THE BORROWER, KEYBANK AND KBCM
IRREVOCABLY AGREE TO WAIVE TRIAL BY JURY IN ANY SUIT, ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM BROUGHT BY OR ON BEHALF OF ANY PARTY RELATED TO OR ARISING OUT OF THE TRANSACTIONS, THIS COMMITMENT LETTER, THE TERM SHEET OR THE PERFORMANCE OF SERVICES
HEREUNDER. 
 This Commitment Letter is delivered to you on the understanding that neither this Commitment Letter or the Term
Sheet nor any of their terms or substance shall be disclosed, directly or indirectly, to any other person except (a) to your officers, agents and advisors (other than commercial lenders) who are directly involved in the consideration of this
matter or (b) as may be compelled in a judicial or administrative proceeding or as otherwise required by law (in which case you agree to inform us promptly thereof). Officers, directors, employees and agents of KBCM and KeyBank and their
affiliates shall at all times have the right to share amongst themselves information received from you and your affiliates and your officers, directors, employees and agents, 
 You acknowledge that KBCM, KeyBank and any of their affiliates may be providing debt financing, equity capital or other services (including financial advisory services) to other companies in respect of
which you may have conflicting interests regarding the transactions described herein and otherwise. Neither KBCM nor KeyBank nor any of their affiliates will use confidential information obtained from you by virtue of the transactions contemplated
by this 

  
 -4-

 
tetter or their other relationships with you in connection with the performance by KBCM or KeyBank or any of their affiliates of services for other companies, and neither KBCM nor KeyBank nor any
of their affiliates will furnish any such information to other companies, You also acknowledge that KBCM, KeyBank and their affiliates have no obligation to use in connection with the transactions contemplated by this letter, or to furnish to you,
confidential information obtained from other companies. 
 The compensation, reimbursement, indemnification and confidentiality
provisions contained herein shall remain in full force and effect regardless of whether definitive financing documentation shall be executed and delivered and notwithstanding the termination of this Commitment Letter or KeyBank’s commitment
hereunder; provided, that your obligations under this Commitment Letter, other than those arising under the fourth, fifth and tenth paragraphs hereof, shall automatically terminate and be superseded by the provisions of the definitive documentation
relating to the Facility upon the initial funding thereunder, and you shall automatically be released from all liability in connection therewith at such time. 
 You hereby authorize KBCM and KeyBank, at their respective sole expense, but without any prior approval by you, to publish such tombstones and give such other publicity to the Facility as each may from
time to time determine in its sole discretion. The foregoing authorization shall remain in effect unless the Borrower notifies each of KBCM and KeyBank in writing that such authorization is revoked. 

If the foregoing correctly sets forth our agreement, please indicate your acceptance of the terms hereof and of the Term Sheet by
returning to us executed counterparts hereof not later than 5:00 p.m., New York City time, on April 8, 2011. KeyBank’s commitment and KBCM’s agreements herein will expire at such time in the event KeyBank has not received such,
executed counterparts in accordance with the immediately preceding sentence. This Commitment Letter and Term Sheet supersede any and all prior versions hereof and thereof. 
 KeyBank and KBCM are pleased to have been given the opportunity to assist you in connection with this important financing. 

  
 -5-

 
					
	Very truly yours,
	
	KEYBANK NATIONAL ASSOCIATION
		
	By:	 	/s/ Henry A. Alonso
		 	Name:	 	Henry A. Alonso
		 	Title:	 	Senior Vice President
	
	KEYBANK CAPITAL MARKETS, INC.
		
	By:	 	/s/ Jay Johns
		 	Name:	 	Jay Johns
		 	Title:	 	Managing Director

  

					
	 Accepted and agreed to as of
 the date First written above by;

	
	SUNRISE SENIOR LIVING, INC.
		
	By:	 	/s/ Marc Richards
		 	Name:	 	Marc Richards
		 	Title:	 	Chief Financial Officer

  
 -6-Purchase Agreement

 Exhibit 10.3 
 Execution Version 
 $75,000,000 

SUNRISE SENIOR LIVING, INC. 
 5.00% JUNIOR SUBORDINATED CONVERTIBLE NOTES DUE 2041 
 PURCHASE AGREEMENT

 April 14, 2011 

 April 14, 2011 
 Stifel, Nicolaus & Company, Incorporated 
 On behalf of itself and the
several Initial Purchasers named in Schedule I 
 hereto 
 c/o Stifel, Nicolaus & Company, Incorporated 
        390
Park Avenue, 2nd Floor 
        New York, New York 10022 
 Ladies and Gentlemen: 
 Sunrise Senior Living, Inc, a Delaware corporation (the
“Company”), proposes to issue and sell to the several purchasers named in Schedule I hereto (the “Initial Purchasers”) $75,000,000 principal amount of its 5.00% Junior Subordinated Convertible Notes due 2041 (the
“Firm Securities”) to be issued pursuant to the provisions of an Indenture dated as of the Closing Date (as defined in Section 4) (the “Indenture”) between the Company and Bank of New York Mellon Trust Company,
National Association, as Trustee (the “Trustee”). The Company also proposes to issue and sell to the Initial Purchasers not more than an additional $11,250,000 principal amount of its 5.00% Junior Subordinated Convertible Notes due
2041 (the “Additional Securities”) if and to the extent that you, as Manager of the offering, shall have determined to exercise, on behalf of the Initial Purchasers, the right to purchase such 5.00% Junior Subordinated Convertible
Notes due 2041 granted to the Initial Purchasers in Section 2 hereof. The Firm Securities and the Additional Securities are hereinafter collectively referred to as the “Securities”. The Securities will be convertible into
shares of common stock, par value $0.01, of the Company (the “Underlying Securities”). 
 The Securities and
the Underlying Securities will be offered without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to qualified institutional buyers in compliance with the exemption from registration provided by
Rule 144A under the Securities Act. 
 In connection with the sale of the Securities, the Company has prepared a preliminary
offering memorandum (the “Preliminary Memorandum”) and will prepare a final offering memorandum (the “Final Memorandum”) including or incorporating by reference a description of the terms of the Securities and the
Underlying Securities, the terms of the offering and a description of the Company. For purposes of this Agreement, “Additional Written Offering Communication” means any written communication (as defined in Rule 405 under the
Securities Act) that constitutes an offer to sell or a solicitation of an offer to buy the Securities other than the Preliminary Memorandum or the Final Memorandum, and “Time of Sale Memorandum” means the Preliminary Memorandum
together with the Additional Written Offering Communications, if 

 
any, each identified in Schedule II hereto. As used herein, the terms Preliminary Memorandum, Time of Sale Memorandum and Final Memorandum shall include the documents, if any, incorporated by
reference therein on the date hereof. The terms “supplement”, “amendment” and “amend” as used herein with respect to the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum or
any Additional Written Offering Communication shall include all documents subsequently filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), that are deemed to be incorporated by reference therein. 
 1. Representations and
Warranties. The Company represents and warrants to, and agrees with, you that: 
 (a)(i) Each document, if
any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum complied or will comply when so filed in all material respects with the Exchange
Act and the applicable rules and regulations of the Commission thereunder, (ii) the Time of Sale Memorandum does not, and at the time of each sale of the Securities in connection with the offering when the Final Memorandum is not yet available
to prospective purchasers and at the Closing Date (as defined in Section 4), the Time of Sale Memorandum, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iii) the Preliminary Memorandum does not contain and the Final Memorandum, in the form used by the Initial
Purchasers to confirm sales and on the Closing Date (as defined in Section 4), will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum based
upon information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through you expressly for use therein. 
 (b) Except for the Additional Written Offering Communications, if any, identified in Schedule II hereto, and electronic road shows, if any, furnished to you before first use, the Company has not prepared,
used or referred to, and will not, without your prior consent, prepare, use or refer to, any Additional Written Offering Communication. 

  
 2 

 (c) The Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of the State of Delaware, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and is
in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not individually or
in the aggregate have a material adverse effect on the condition (financial or other), business, properties or results of operations of the Company and its consolidated subsidiaries (each, a “Subsidiary”, and together, its
“Subsidiaries”), taken as a whole (a “Material Adverse Effect”). 
 (d) Each of
Sunrise Senior Living Services, Inc., Sunrise Senior Living Management, Inc., Sunrise North Senior Living LTD, Sunrise Senior Living Investments, Inc. and Sunrise Development, Inc. (the “Material Operating Subsidiaries”) and each
other Subsidiary of the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its
business as described in the Time of Sale Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification,
except to the extent that the failure to be so qualified or be in good standing would not individually or in the aggregate have a Material Adverse Effect; all of the issued shares of capital stock of each Subsidiary of the Company have been duly and
validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims, except as disclosed in the Time of Sale Memorandum or the Final
Memorandum, or except with respect to any Subsidiary that is not a Material Operating Subsidiary, as would not individually or in the aggregate have a Material Adverse Effect. 

(e) This Agreement has been duly authorized, executed and delivered by the Company. 

(f) The authorized capital stock of the Company conforms in all material respects as to legal matters to the description
thereof contained in each of the Time of Sale Memorandum and the Final Memorandum. 
 (g) The shares of common
stock outstanding prior to the issuance of the Securities have been duly authorized and are validly issued, fully paid and non-assessable. 

  
 3 

 (h) The Securities have been duly authorized and, when executed and
authenticated in accordance with the provisions of the Indenture and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be valid and binding obligations of the Company, enforceable in accordance
with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability and will be entitled to the benefits of the Indenture pursuant to which such
Securities are to be issued. 
 (i) The Underlying Securities issuable upon conversion of the Securities have
been duly authorized and reserved and, when issued upon conversion of the Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the issuance of the Underlying Securities will not be
subject to any preemptive or similar rights. 
 (j) The Indenture has been duly authorized, and when executed and
delivered by the Company on the Closing Date, will be a valid and binding agreement of, the Company, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally
and equitable principles of general applicability. 
 (k) The Securities conform in all material respects to the
description thereof contained in each of the Time of Sale Memorandum and the Final Memorandum under “Description of Notes”. 
 (l) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement, the Indenture and the Securities will not contravene any provision of
applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding upon the Company or any of its Subsidiaries that is material to the Company and its Subsidiaries, taken as a whole, or any
judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any Subsidiary, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for
the performance by the Company of its obligations under this Agreement, the Indenture or the Securities, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Securities.

 (m) Since the date of the latest audited financial statements included in the Time of Sale Memorandum, there
has not occurred any 

  
 4 

 
material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company
and its Subsidiaries, taken as a whole, except as set forth in the Time of Sale Memorandum provided to prospective purchasers of the Securities. 
 (n) Other than proceedings accurately described in all material respects in the Time of Sale Memorandum, there are no legal or governmental proceedings pending or threatened to which the Company or any of
its Subsidiaries is a party or to which any of the properties of the Company or any of its Subsidiaries is subject that would reasonably be expected to have a Material Adverse Effect, or would materially and adversely affect the power or ability of
the Company to perform its obligations under this Agreement, the Indenture or the Securities or to consummate the transactions contemplated by the Time of Sale Memorandum. 

(o) The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and
local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits,
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such
noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, have a
Material Adverse Effect. 
 (p) There are no costs or liabilities associated with Environmental Laws (including,
without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential
liabilities to third parties) which would, individually or in the aggregate, have a Material Adverse Effect. 

(q) The Company is not, and after giving effect to the offering and sale of the Securities and the application of the
proceeds thereof as described in the Final Memorandum will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”).

  
 5 

 (r) Neither the Company nor any affiliate (as defined in Rule 501(b) of
Regulation D under the Securities Act, an “Affiliate”) of the Company has directly, or through any agent, (i) sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in
the Securities Act) which is or will be integrated with the sale of the Securities in a manner that would require the registration under the Securities Act of the Securities or (ii) offered, solicited offers to buy or sold the Securities by any
form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act. 

(s) It is not necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchasers in the
manner contemplated by this Agreement to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended. 

(t) The Securities satisfy the requirements set forth in Rule 144A(d)(3) under the Securities Act. 

(u) Neither the Company nor any of its Subsidiaries or affiliates, nor any director or officer, nor, to the Company’s
knowledge, any employee, agent or representative of the Company or of any of its Subsidiaries or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving
of money, property, gifts or anything else of value, directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to influence official action or secure an improper advantage; and the
Company and its Subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintain and will continue to maintain policies and procedures reasonably designed to promote and
achieve compliance with such laws and with the representation and warranty contained herein. 
 (v) The
operations of the Company and its Subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III
of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable 

  
 6 

 
anti-money laundering statutes of jurisdictions where the Company and its Subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its Subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. 

(w)(i) Neither the Company nor any of its Subsidiaries, nor any director or officer thereof, nor, to the Company’s
knowledge, any employee, agent, affiliate or representative of the Company or any of its Subsidiaries, is an individual or entity (“Person”) that is, or is owned or controlled by a Person that is: 

(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign
Assets Control (“OFAC”) , the United Nations Security Council (“UNSC”), the European Union (“EU”), Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority
(collectively, “Sanctions”), nor 
 (B) located, organized or resident in a country or
territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran, Libya, North Korea, Sudan and Syria). 
 (ii) The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person:

 (A) to fund or facilitate any activities or business of or with any Person or in any country or territory
that, at the time of such funding or facilitation, is the subject of Sanctions; or 
 (B) in any other manner
that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). 

(iii) For the past 5 years, the Company and its Subsidiaries have not knowingly engaged in, are not now

  
 7 

 
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of
Sanctions. 
 (x) The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax
returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in the aggregate, have a Material Adverse Effect) and have paid all taxes required to
be paid thereon (except for cases in which the failure to file or pay would not, individually or in the aggregate, have a Material Adverse Effect, or, except as currently being contested in good faith and for which reserves required by U.S. GAAP
have been created in the financial statements of the Company), and no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had (nor does the Company nor any of its Subsidiaries have any notice or knowledge
of any tax deficiency which could reasonably be expected to be determined adversely to the Company or its Subsidiaries and which could reasonably be expected to have) a Material Adverse Effect. 

(y) The financial statements and the related notes thereto of the Company and its Subsidiaries included or incorporated by
reference in the Time of Sale Memorandum present fairly, in all material respects, the financial position of the Company and its Subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the
periods specified; such financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods covered thereby. 

(z) The Company and its Subsidiaries have good and marketable title in fee simple to all real property and good and
marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries as described in the Time of Sale Memorandum, in each case free and clear of all liens, encumbrances and defects except such
as are described in the Time of Sale Memorandum or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries; and any real property
and buildings held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of
such property and buildings by the Company and its 

  
 8 

 
Subsidiaries, in each case except as described in the Time of Sale Memorandum. 
 (aa) No labor dispute with the employees of the Company or any of its Subsidiaries exists, except as described in the Time of Sale Memorandum, or, to the knowledge of the Company, is threatened that would
reasonably be expected to have a Material Adverse Effect; and the Company is not aware of any existing or threatened labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would reasonably be expected
to have a Material Adverse Effect. 
 (bb) The Company and each of its Subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its Subsidiaries has been refused any insurance coverage
sought or applied for; and neither the Company nor any of its Subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect, except as described in the Time of Sale Memorandum. 

(cc) The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their respective businesses as described in the Time of Sale Memorandum, except where the failure to possess the same would not, individually or in the aggregate, have a Material
Adverse Effect, and neither the Company nor any of its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect, except as described in the Time of Sale Memorandum. 

(dd) The Company and each of its Subsidiaries maintain a system of “internal control over financial reporting”
(as defined in Rule 13a-15 of the Exchange Act) sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate 

  
 9 

 
action is taken with respect to any differences. Except as described in the Time of Sale Memorandum, since the end of the Company’s most recent audited fiscal year, there has been
(i) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the Company’s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company’s internal control over financial reporting. 
 (ee) The
Company has not taken and will not take, directly or indirectly, any action designed to or that might be reasonably expected to (i) cause or result in stabilization or manipulation of the price of the Securities or the Underlying Securities to
facilitate the sale or resale of the Securities (provided, however, that this paragraph shall not apply to any stabilization activities conducted by the Initial Purchasers, who shall remain solely responsible for such activities), or
(ii) violate Regulation M under the Exchange Act. 
 (ff) Except for the matter described in the
Company’s annual report on Form 10-K for the fiscal year ended December 31, 2009 under Item 3 under the caption “Trinity OIG Investigation and Qui Tam Action,” neither the Company nor its Subsidiaries, nor any director or
officer, nor to the knowledge of the Company, any employee or other agent of the Company or any of its Subsidiaries, has engaged on behalf of the Company, directly or indirectly, in (i) any activities which are prohibited under Medicare and
Medicaid statutes or any regulations promulgated pursuant to such statutes, or (ii) any activities which are prohibited under related state or local statutes or regulations or any rules of professional conduct, which activities in (i) and
(ii) would, individually or in the aggregate, have a Material Adverse Effect including the following: (A) knowingly and willfully making or causing to be made a false statement or representation of a material fact in connection with the
receipt of or claim for any benefit or payment under the Medicare or Medicaid program or from any other third party payor; (B) failing to disclose knowledge by a claimant of the occurrence of any event affecting the initial or continued right
to any benefit or payment under the Medicare or Medicaid program or from any other third party payor on its own behalf or on behalf of another, with intent to secure such benefit or payment fraudulently; (C) knowingly and willfully offering,
paying, soliciting or receiving any remuneration, in cash or in kind (1) in return for referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in
part by Medicare or Medicaid or any other third party payor, or (2) in return for purchasing, leasing or ordering or arranging for, or recommending the purchasing, leasing or ordering of, any good, facility, service, or item for which payment
may be made in whole or in part by Medicare or Medicaid or any other third party payor; (D) knowingly 

  
 10 

 
and willfully referring an individual to a person or entity with which it has ownership or other financial arrangements (where applicable federal or state law prohibits such referrals); and
(E) knowingly and willfully violating any enforcement initiative instituted by any governmental agency (including the Office of the Inspector General and the Department of Justice). 

2. Agreements to Sell and Purchase. The Company hereby agrees to sell to the several Initial Purchasers, and each Initial
Purchaser, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective principal amount of Firm Securities
set forth in Schedule I hereto opposite its name at a purchase price of 100% of the principal amount thereof (the “Purchase Price”) plus accrued interest, if any, to the Closing Date. 

On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company
agrees to sell to the Initial Purchasers the Additional Securities, and the Initial Purchasers shall have the right to purchase, severally and not jointly, up to $11,250,000 principal amount of Additional Securities at the Purchase Price plus
accrued interest, if any, to the date of payment and delivery. You may exercise this right on behalf of the Initial Purchasers in whole or from time to time in part by giving written notice not later than 30 days after the date of this Agreement.
Any exercise notice shall specify the principal amount of Additional Securities to be purchased by the Initial Purchasers and the date on which such Additional Securities are to be purchased. Each purchase date must be at least one business day
after the written notice is given and may not be earlier than the closing date for the Firm Securities nor later than ten business days after the date of such notice. On each day, if any, that Additional Securities are to be purchased (an
“Option Closing Date”), each Initial Purchaser agrees, severally and not jointly, to purchase the principal amount of Additional Securities (subject to such adjustments to eliminate fractional Securities as you may determine) that
bears the same proportion to the total principal amount of Additional Securities to be purchased on such Option Closing Date as the principal amount of Firm Securities set forth in Schedule I opposite the name of such Initial Purchaser bears to
the total principal amount of Firm Securities. 
 3. Terms of Offering. You have advised the Company that the Initial
Purchasers will make an offering of the Securities purchased by the Initial Purchasers hereunder as soon as practicable after this Agreement is entered into as in your judgment is advisable. 

4. Payment and Delivery. Payment for the Firm Securities shall be made to the Company in Federal or other funds immediately
available in New 

  
 11 

 
York City against delivery of such Firm Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on April 20, 2011, or at such other time
on the same or such other date, not later than April 27, 2011, as shall be designated in writing by you. The time and date of such payment are hereinafter referred to as the “Closing Date.” 

Payment for any Additional Securities shall be made to the Company in Federal or other funds immediately available in New York City
against delivery of such Additional Securities for the respective accounts of the several Initial Purchasers at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section 2 or at such other time
on the same or on such other date, in any event not later than May 27, 2011, as shall be designated in writing by you. 

The Securities shall be in definitive form or global form, as specified by you, and registered in such names and in such denominations as
you shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Securities shall be delivered to you on the Closing Date or an Option Closing Date, as the
case may be, for the respective accounts of the several Initial Purchasers, with any transfer taxes payable in connection with the transfer of the Securities to the Initial Purchasers duly paid, against payment of the Purchase Price therefor plus
accrued interest, if any, to the date of payment and delivery. 
 5. Conditions to the Initial Purchasers’
Obligations. The several obligations of the Initial Purchasers to purchase and pay for the Firm Securities on the Closing Date are subject to the following conditions: 

(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date: 

(i) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded the Company or any of the securities of the Company or any of its Subsidiaries or in the rating outlook for the
Company by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act; and 
 (ii) there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and
its Subsidiaries, taken as a whole, from that set forth in the Time of Sale Memorandum as of the date of this 

  
 12 

 
Agreement provided to the prospective purchasers of the Securities that, in your judgment, is material and adverse and that makes it, in your judgment, impracticable to market the Securities on
the terms and in the manner contemplated in the Time of Sale Memorandum. 
 (b) The Initial Purchasers shall have
received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect set forth in Section 5(a)(i) and to the effect that the representations and warranties of the Company contained
in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.

 The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to
proceedings threatened. 
 (c) The Initial Purchasers shall have received on the Closing Date an opinion of
Maslon Edelman Borman & Brand, LLP, outside counsel for the Company, dated the Closing Date, to the effect set forth in Exhibit A. Such opinion shall be rendered to the Initial Purchasers at the request of the Company and shall so state
therein. 
 (d) The Initial Purchasers shall have received on the Closing Date an opinion of David Haddock,
General Counsel of the Company, dated the Closing Date, to the effect set forth in Exhibit B. Such opinion shall be rendered to the Initial Purchasers at the request of the Company and shall so state therein. 

(e) The Initial Purchasers shall have received on the Closing Date an opinion of Davis Polk & Wardwell LLP,
counsel for the Initial Purchasers, dated the Closing Date, covering such matters as they shall request. 
 (f)
The Initial Purchasers shall have received on each of the date hereof and the Closing Date a letter, dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers, from Ernst &
Young LLP, independent public accountants, containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial
information of the Company and AL US Development Venture LLC contained in or incorporated by reference into the Time of Sale Memorandum and the Final Memorandum; provided that 

  
 13 

 
the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date hereof. 

(g) The “lock-up” agreements, each substantially in the form of Exhibit C hereto, between you and certain
officers and directors of the Company relating to sales and certain other dispositions of shares of common stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date.

 (h) A commitment letter with respect to the Company’s new credit facility with KeyBank National
Association shall have been entered into as described in the Time of Sale Memorandum and the Final Memorandum, and the Initial Purchasers shall have been furnished with documentation evidencing the execution of such commitment letter in a form
reasonably satisfactory to the Initial Purchasers. 
 (i) The Company has obtained a consent, dated as of
April 13, 2011, from the lenders under its credit agreement dated as of December 2, 2005, as amended by and among the Company as borrower and Bank of America, N.A., as administrative agent, swing line lender, and l/c issuer, Wachovia Bank,
National Association, as syndication agent, and other lender parties thereto, to permit the offering of the Securities. 
 The
several obligations of the Initial Purchasers to purchase Additional Securities hereunder are subject to the delivery to you on the applicable Option Closing Date of such documents as you may reasonably request with respect to the good standing of
the Company, the due authorization ,execution and authentication of the Additional Securities to be sold on such Option Closing Date and other matters related to the execution and authentication of such Additional Securities. 

6. Covenants of the Company. The Company covenants with each Initial Purchaser as follows: 

(a) To furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day
next succeeding the date of this Agreement and during the period mentioned in Section 6(d) or (e), as many copies of the Time of Sale Memorandum, the Final Memorandum, any documents incorporated by reference therein and any supplements and
amendments thereto as you may reasonably request. 
 (b) Before amending or supplementing the Preliminary
Memorandum, the Time of Sale Memorandum or the Final Memorandum, to furnish to you a copy of each such proposed amendment or supplement 

  
 14 

 
and not to use any such proposed amendment or supplement to which you reasonably object. 
 (c) To furnish to you a copy of each proposed Additional Written Offering Communication to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed
Additional Written Offering Communication to which you reasonably object. 
 (d) If the Time of Sale Memorandum
is being used to solicit offers to buy the Securities at a time when the Final Memorandum is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the
Time of Sale Memorandum in order to make the statements therein, in the light of the circumstances, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Time of Sale Memorandum to
comply with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchasers and to any dealer upon request, either amendments or supplements to the Time of Sale Memorandum so that the statements in the Time of Sale
Memorandum as so amended or supplemented will not, in the light of the circumstances when delivered to a prospective purchaser, be misleading or so that the Time of Sale Memorandum, as amended or supplemented, will comply with applicable law.

 (e) If, during such period after the date hereof and prior to the date on which all of the Securities shall
have been sold by the Initial Purchasers, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Final Memorandum in order to make the statements therein, in the light of the circumstances when the
Final Memorandum is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Initial Purchasers, it is necessary to amend or supplement the Final Memorandum to comply with applicable law, forthwith to prepare and furnish,
at its own expense, to the Initial Purchasers, either amendments or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will not, in the light of the circumstances when the Final
Memorandum is delivered to a purchaser, be misleading or so that the Final Memorandum, as amended or supplemented, will comply with applicable law. 
 (f) To endeavor to qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as you shall reasonably request; provided, that the Company shall not be required
to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such 

  
 15 

 
jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in
any such jurisdiction if it is not otherwise so subject. 
 (g) Whether or not the transactions contemplated in
this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the
Company’s counsel and the Company’s accountants in connection with the issuance and sale of the Securities and all other fees or expenses in connection with the preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the
Final Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the Company and any amendments and supplements to any of the foregoing, including all printing costs associated therewith, and
the delivering of copies thereof to the Initial Purchasers, in the quantities herein above specified, (ii) all costs and expenses related to the transfer and delivery of the Securities to the Initial Purchasers, including any transfer or other
taxes payable thereon, (iii) the cost of printing or producing any Blue Sky or legal investment memorandum in connection with the offer and sale of the Securities under state securities laws and all expenses in connection with the qualification
of the Securities for offer and sale under state securities laws as provided in Section 6(f) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Initial Purchasers in connection with such qualification and
in connection with the Blue Sky or legal investment memorandum, (iv) any fees charged by rating agencies for the rating of the Securities, (v) the fees and expenses, if any, incurred in connection with the admission of the Securities for
trading on any appropriate market system, (vi) the costs and charges of the Trustee and any transfer agent, registrar or depositary, (vii) the cost of the preparation, issuance and delivery of the Securities, (viii) the costs and
expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities, including, without limitation, expenses associated with the preparation or
dissemination of any electronic road show, expenses associated with production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company,
travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show, (ix) the document production charges and expenses associated with
printing this Agreement and (x) all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not 

  
 16 

 
otherwise made in this Section. It is understood, however, that except as provided in this Section, Section 8, and the last paragraph of Section 10, the Initial Purchasers will pay all
of their costs and expenses, including fees and disbursements of their counsel, transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may make. 

(h) Neither the Company nor any Affiliate will sell, offer for sale or solicit offers to buy or otherwise negotiate in
respect of any security (as defined in the Securities Act) which could be integrated with the sale of the Securities in a manner which would require the registration under the Securities Act of the Securities. 

(i) Not to solicit any offer to buy or offer or sell the Securities or the Underlying Securities by means of any form of
general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act. 

(j) While any of the Securities or the Underlying Securities remain “restricted securities” within the meaning
of the Securities Act, to make available, upon request, to any seller of such Securities the information specified in Rule 144A(d)(4) under the Securities Act, unless the Company is then subject to Section 13 or 15(d) of the Exchange Act.

 (k) During the period of two years after the Closing Date or any Option Closing Date, if later, the Company
will not be, nor will it become, an open-end investment company, unit investment trust or face-amount certificate company that is or is required to be registered under Section 8 of the Investment Company Act. 

(l) None of the Company, its Affiliates or any person acting on its or their behalf (other than the Initial Purchasers)
will engage in any directed selling efforts (as that term is defined in Regulation S) with respect to the Securities, and the Company and its Affiliates and each person acting on its or their behalf (other than the Initial Purchasers) will comply
with the offering restrictions requirement of Regulation S. 
 (m) During the period of six months after the
Closing Date or any Option Closing Date, if later, the Company will not, and will not permit any of its affiliates (as defined in Rule 144 under the Securities Act) to resell any of the Securities or the Underlying Securities which constitute
“restricted securities” under Rule 144 that have been reacquired by any of them. 

  
 17 

 (n) Not to take any action prohibited by Regulation M under the
Exchange Act in connection with the distribution of the Securities contemplated hereby. 
 (o) The Company will
reserve and keep available at all times, free of pre-emptive rights, shares of common stock for the purpose of enabling the Company to satisfy all obligations to issue the Underlying Securities upon conversion of the Securities. The Company will use
its reasonable best efforts to cause the Underlying Securities to be listed on the New York Stock Exchange. 

(p) The Company will apply the net proceeds from the sale of the Securities as described in the Time of Sale Memorandum
and the Final Memorandum under the heading “Use of Proceeds”. 
 The Company also agrees that, without the prior
written consent of Stifel, Nicolaus & Company, Incorporated on behalf of the Initial Purchasers, it will not, during the period ending 90 days after the date of the Final Memorandum, (1) offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into
or exercisable or exchangeable for common stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of common stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a) the sale of the Securities under this Agreement,
(b) the issuance by the Company of any shares of common stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof of which the Initial Purchasers have been advised in writing, (c) the
grants of awards by the Company under its 2008 Omnibus Incentive Plan, as amended, or (d) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of common stock, provided that such
plan does not provide for the transfer of common stock during the 90-day restricted period and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf
of the undersigned or the Company. 
 7. Offering of Securities; Restrictions on Transfer. (a) Each Initial
Purchaser, severally and not jointly, represents and warrants that such Initial Purchaser is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). Each Initial Purchaser, severally and not
jointly, agrees with the Company that (i) it will not solicit offers for, or offer or sell, such Securities by any form of general solicitation or general advertising (as those 

  
 18 

 
terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act and (ii) it will solicit
offers for such Securities only from, and will offer such Securities only to, persons that it reasonably believes to be QIBs, that in connection with purchasing such Securities are deemed to have represented and agreed as provided in the Final
Memorandum under the caption “Transfer Restrictions; Notice to Investors”. 
 (b) The Company agrees
that the Initial Purchasers may provide copies of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum and any other agreements or documents relating thereto, including without limitation, the Indenture, to Xtract Research
LLC (“Xtract”), following completion of the offering, for inclusion in an online research service sponsored by Xtract, access to which shall be restricted by Xtract to QIBs. 

8. Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless each Initial Purchaser, each person, if
any, who controls any Initial Purchaser within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate of any Initial Purchaser within the meaning of Rule 405 under the Securities
Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue
statement or alleged untrue statement of a material fact contained in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred to by the Company, any
road show as defined in Rule 433(h) under the Securities Act or the Final Memorandum or any amendment or supplement thereto, or caused by any omission or alleged omission to state therein a material fact necessary to make the statements therein in
the light of the circumstances under which they were made not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon
information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through you expressly for use therein. 
 (b) Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers and each person, if any, who controls the Company within the meaning
of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Initial Purchaser, but only with reference to information relating to such Initial
Purchaser furnished to the Company in writing by such Initial Purchaser through you expressly for use in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering Communication

  
 19 

 
prepared by or on behalf of, used by or referred to by the Company, any road show, or the Final Memorandum or any amendment or supplement thereto. 

(c) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect
of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be sought (the “indemnifying party”) in
writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded parties)
include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the indemnifying party
shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local
counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by Stifel, Nicolaus & Company, Incorporated, in the case of parties indemnified
pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled
with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party
agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and
(ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, 

  
 20 

 
without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party
and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 

(d) To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable
by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Initial Purchasers on the other hand
from the offering of the Securities or (ii) if the allocation provided by clause 8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in
clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Initial Purchasers on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well
as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Initial Purchasers on the other hand in connection with the offering of the Securities shall be deemed to be in the same respective
proportions as the net proceeds from the offering of the Securities (before deducting expenses) received by the Company and the total discounts and commissions received by the Initial Purchasers bear to the aggregate offering price of the
Securities. The relative fault of the Company on the one hand and of the Initial Purchasers on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission
or alleged omission to state a material fact relates to information supplied by the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Initial Purchasers’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective principal amount of Securities they have purchased hereunder, and not joint. 

(e) The Company and the Initial Purchasers agree that it would not be just or equitable if contribution pursuant to this
Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in

  
 21 

 
Section 8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include,
subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no
Initial Purchaser shall be required to contribute any amount in excess of the amount by which the total price at which the Securities resold by it in the initial placement of such Securities were offered to investors exceeds the amount of any
damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may
otherwise be available to any indemnified party at law or in equity. 
 (f) The indemnity and contribution
provisions contained in this Section 8 and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this
Agreement, (ii) any investigation made by or on behalf of any Initial Purchaser, any person controlling any Initial Purchaser or any affiliate of any Initial Purchaser or by or on behalf of the Company, its officers or directors or any person
controlling the Company and (iii) acceptance of and payment for any of the Securities. 
 9. Termination. The
Initial Purchasers may terminate this Agreement by notice given by you to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on,
or by, as the case may be, any of the New York Stock Exchange, the American Stock Exchange, the NASDAQ Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading of any
securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any
moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or
crisis that, in your judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in your judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the
Securities on the 

  
 22 

 
terms and in the manner contemplated in the Time of Sale Memorandum or the Final Memorandum. 
 10. Effectiveness; Defaulting Initial Purchasers. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. 

If, on the Closing Date, or an Option Closing Date, as the case may be, any one or more of the Initial Purchasers shall fail or refuse to
purchase Securities that it or they have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase is not more
than one-tenth of the aggregate principal amount of Securities to be purchased on such date, the other Initial Purchasers shall be obligated severally in the proportions that the principal amount of Firm Securities set forth opposite their
respective names in Schedule I bears to the aggregate principal amount of Firm Securities set forth opposite the names of all such non-defaulting Initial Purchasers, or in such other proportions as you may specify, to purchase the Securities
which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on such date; provided that in no event shall the principal amount of Securities that any Initial Purchaser has agreed to purchase pursuant
to this Agreement be increased pursuant to this Section 10 by an amount in excess of one-ninth of such principal amount of Securities without the written consent of such Initial Purchaser. If, on the Closing Date any Initial Purchaser or
Initial Purchasers shall fail or refuse to purchase Firm Securities which it or they have agreed to purchase hereunder on such date and the aggregate principal amount of Securities with respect to which such default occurs is more than one-tenth of
the aggregate principal amount of Firm Securities to be purchased on such date, and arrangements satisfactory to you and the Company for the purchase of such Firm Securities are not made within 36 hours after such default, this Agreement shall
terminate without liability on the part of any non-defaulting Initial Purchaser or of the Company. In any such case either you or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order
that the required changes, if any, in the Time of Sale Memorandum, the Final Memorandum or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Initial Purchaser or Initial Purchasers shall fail or refuse to
purchase Additional Securities and the aggregate principal amount of Additional Securities with respect to which such default occurs is more than one-tenth of the aggregate principal amount of Additional Securities to be purchased on such Option
Closing Date, the non-defaulting Initial Purchasers shall have the option to (a) terminate their obligation hereunder to purchase the Additional Securities to be sold on such Option Closing Date or (b) purchase not less than the principal
amount of Additional Securities that such non-defaulting Initial Purchasers would have been obligated to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Initial

  
 23 

 
Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 
 If this Agreement shall be terminated by the Initial Purchasers, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions
of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Initial Purchasers or such Initial Purchasers as have so terminated this Agreement with respect to
themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Initial Purchasers in connection with this Agreement or the offering contemplated hereunder. 

11. Entire Agreement. (a) This Agreement, together with any contemporaneous written agreements and any prior written
agreements (to the extent not superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the Company and the Initial Purchasers with respect to the preparation of the Preliminary Memorandum,
the Time of Sale Memorandum, the Final Memorandum, the conduct of the offering, and the purchase and sale of the Securities. 
 (b) The Company acknowledges that in connection with the offering of the Securities: (i) the Initial Purchasers have acted at arms length, are not agents of, and owe no fiduciary duties to, the
Company or any other person, (ii) the Initial Purchasers owe the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement) if any, and (iii) the
Initial Purchasers may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Initial Purchasers arising from an alleged breach of fiduciary duty in
connection with the offering of the Securities. 
 12. Counterparts. This Agreement may be signed in two or more
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 
 13. Applicable Law. (a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. 

(b) Except as set forth below, no claim arising out of or in any way relating to this Agreement may be commenced,
prosecuted or continued in any court other than the courts of the State of New York located in the City and County of New York or in the United States District Court for the Southern District of New York, which courts shall have

  
 24 

 
jurisdiction over the adjudication of such matters, and the Company consents to the jurisdiction of such courts and personal service with respect thereto. The Company hereby consents to personal
jurisdiction, service and venue in any court in which any claim arising out of or in any way relating to this Agreement is brought by any third party against any Initial Purchaser or any indemnified party. 

14. Headings. The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be
deemed a part of this Agreement. 
 15. Notices. All communications hereunder shall be in writing and effective only upon
receipt and if to the Initial Purchasers shall be delivered, mailed or sent to Stifel, Nicolaus & Company, One South Street, Baltimore, MD 21202, Attention: Michael A. Gilbert, Deputy General Counsel; and if to the Company shall be
delivered, mailed or sent to 7900 Westpark Drive McLean, VA 22102, Attention: General Counsel. 
 [Signature Page Follows]

  
 25 

 
					
	Very truly yours,
	
	SUNRISE SENIOR LIVING, INC.
		
	By:	 	/s/ Mark S. Ordan
		 	Name:	 	Mark S. Ordan
		 	Title:	 	Chief Executive Officer

  
 [Purchase
Agreement] 

					
	Accepted as of the date hereof
	
	Stifel, Nicolaus & Company, Incorporated Acting on behalf of itself and the several Initial Purchasers named in Schedule I hereto.
		
	By:	 	Stifel, Nicolaus & Company, Incorporated
		
	By:	 	/s/ Craig M. DeDomenico
		 	Name:	 	Craig M. DeDomenico
		 	Title:	 	Managing Director

  
 [Purchase
Agreement] 

 SCHEDULE I 

 

					
	 Initial Purchaser
	  	Principal amount of Firm
Securities to be
Purchased	 
	 Stifel, Nicolaus & Company, Incorporated
	  	$	60,000,000	  
	 KeyBanc Capital Markets Inc
	  	$	15,000,000	  
		  	 	 	 
	 Total:
	  	$	75,000,000	  
		  	 	 	 

  
 I-1

 SCHEDULE II 
 Time of Sale Memorandum 
  

	1.	Preliminary Memorandum issued April 14, 2011 

  

	2.	Pricing Term Sheet dated April 14, 2011 

  
 II-1

 EXHIBIT A 
 OPINION OF MASLON EDELMAN BORMAN & BRAND, LLP 
 The opinion of
Maslon Edelman Borman & Brand, LLP to be delivered pursuant to Section 5(c) of the Purchase Agreement shall be to the effect that: 
 A. The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its
property and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and is in good standing in the State of Delaware. 
 B. The Purchase Agreement has been duly authorized, executed and delivered by the Company. 
 C. The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Time of Sale Memorandum and the Final Memorandum. 

D. The Securities have been duly authorized by the Company and, when executed and authenticated in accordance with the provisions of the
Indenture and delivered to and paid for by the Initial Purchasers in accordance with the terms of the Purchase Agreement, will be valid and binding obligations of the Company, enforceable in accordance with their terms, subject to applicable
bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability, and will be entitled to the benefits of the Indenture pursuant to which such Securities are to be issued.

 E. The Underlying Securities reserved for issuance upon conversion of the Securities have been duly authorized and reserved
and, when issued upon conversion of the Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non assessable and the issuance of the Underlying Securities will not be subject to any preemptive or similar
rights under applicable law or the certificate of incorporation or by laws of the Company or, to the best of such counsel’s knowledge, any agreement or other instrument binding upon the Company, which has is set forth on the exhibit list to the
Company’s annual report on Form 10-K for the fiscal year ended December 31, 2010. 
 F. The Indenture has been duly
authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally, concepts
of reasonableness and equitable principles of general applicability. 

  
 A-1

 G. The execution and delivery by the Company of, and the performance by the Company of its
obligations under, the Purchase Agreement, the Indenture and the Securities will not contravene any provision of applicable law or the certificate of incorporation or by laws of the Company or, to the best of such counsel’s knowledge, any
agreement or other instrument binding upon the Company, which is set forth on the exhibit list to the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2010, the term sheet dated April 4, 2011, between the
Company and KeyBank National Association, or, to the best of such counsel’s knowledge, any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any Subsidiary, and no consent, approval,
authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under the Purchase Agreement, the Indenture or the Securities, except such as may be required by the
securities or Blue Sky laws of the various states in connection with the offer and sale of the Securities. 
 H. The Company is
not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Final Memorandum will not be, required to register as an “investment company” as such term is defined
in the Investment Company Act of 1940, as amended. 
 I. The statements relating to legal matters, documents or proceedings
included in (1) the Time of Sale Memorandum and the Final Memorandum under the captions “Description of Notes” and “Description of Capital Stock,” or incorporated by reference in the Time of Sale Memorandum and in the Final
Memorandum, in each case fairly summarize in all material respects such matters, documents or proceedings. 
 J. The statements
in each of the Time of Sale Memorandum and the Final Memorandum under the caption “Material U.S. Federal Income Tax Consequences,” insofar as such statements constitute a summary of the United States federal tax laws referred to therein,
are accurate and fairly summarize in all material respects the United States federal tax laws referred to therein. 
 K. (1) In
the opinion of such counsel each document filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Memorandum or Final Memorandum (except for the financial statements and financial schedules and other financial data
included therein, as to which such counsel need not express any opinion) appeared on its face to be appropriately responsive as of its filing date in all material respects to the Exchange Act and the applicable rules and regulations of the
Commission thereunder and (2) nothing has come to the attention of such counsel that causes such counsel to believe that (A) the Time of Sale Memorandum (except for the financial statements and financial schedules and other financial data,
as to which such counsel need not express any belief) as of the date of the Purchase Agreement or as amended or 

  
 A-2

 
supplemented, if applicable, as of the date such opinion is delivered contained or contains any untrue statement of a material fact or omitted or omits to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading or (B) the Final Memorandum (except for the financial statements and financial schedules and other financial data, as to which such
counsel need not express any belief) when issued contained, or as of the date such opinion is delivered contains, any untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. 
 With respect to the matters referred to in the
paragraph above, counsel may state that his or her opinions and beliefs are based upon his or her participation in the preparation of the Time of Sale Memorandum and the Final Memorandum (and any amendments or supplements thereto) and review and
discussion of the contents thereof and review of the documents incorporated by reference therein, but are without independent check or verification except as specified. 
 L. Based upon the representations, warranties and agreements of the Company in Sections 1(r), 1(t), 6(h), 6(i),6(j) and 6(l) of the Purchase Agreement and of the Initial Purchasers in Section 7 of
the Purchase Agreement, it is not necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchasers as contemplated by the Purchase Agreement and the Preliminary Memorandum and the Final Memorandum or in
connection with the initial resale of such Securities by the Initial Purchasers in accordance with Section 7 of the Purchase Agreement to register the Securities under the Securities Act of 1933 or to qualify the Indenture under the Trust
Indenture Act of 1939, as amended, it being understood that no opinion is expressed as to any subsequent resale of any Security or Underlying Security. 

  
 A-3

 EXHIBIT B 
 OPINION OF DAVID HADDOCK, GENERAL COUNSEL OF THE COMPANY 
 The opinion of
David Haddock, General Counsel of the Company to be delivered pursuant to Section 5(e) of the Purchase Agreement shall be to the effect that: 
 A. The Company is duly qualified to transact business and is in good standing in the State of Virginia. 
 B. Each Material Operating Subsidiary has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and
authority to own its property and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or
leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, individually or in the aggregate, have a Material Adverse Effect; all of the issued shares of capital stock
of each Material Operating Subsidiary have been duly and validly authorized and issued, are fully paid and non-assessable, and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims, except as disclosed in
the Time of Sale Memorandum or the Final Memorandum. 
 C. The execution and delivery by the Company of, and the performance by
the Company of its obligations under, the Purchase Agreement, the Indenture and the Securities will not contravene any provision of applicable law or the certificate of incorporation or by laws of the Company or, to the best of such counsel’s
knowledge, any agreement or other instrument binding upon the Company or any of its Subsidiaries that is material to the Company and its Subsidiaries, taken as a whole, or, to the best of such counsel’s knowledge, any judgment, order or decree
of any governmental body, agency or court having jurisdiction over the Company or any Subsidiary, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the
Company of its obligations under the Purchase Agreement, the Indenture or the Securities, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Securities. 

D. After due inquiry, such counsel does not know of any legal or governmental proceedings pending or threatened to which the Company or
any of its Subsidiaries is a party or to which any of the properties of the Company or any 

  
 B-1

 
of its Subsidiaries is subject other than proceedings fairly summarized in all material respects in the Time of Sale Memorandum and proceedings which such counsel believes are not likely to have
a Material Adverse Effect, or would materially and adversely affect the power or ability of the Company to perform its obligations under the Purchase Agreement, the Indenture or the Securities or to consummate the transactions contemplated by the
Time of Sale Memorandum. 
 E. The statements relating to legal matters, documents or proceedings included in “Item 3.
Legal Proceedings” of the Company’s most recent annual report on Form 10-K, incorporated by reference in the Time of Sale Memorandum and in the Final Memorandum fairly summarize in all material respects such matters, documents or
proceedings. 
 F. (i) In the opinion of such counsel each document filed pursuant to the Exchange Act and incorporated by
reference in the Time of Sale Memorandum or Final Memorandum (except for the financial statements and financial schedules and other financial data included therein, as to which such counsel need not express any opinion) appeared on its face to be
appropriately responsive as of its filing date in all material respects to the Exchange Act and the applicable rules and regulations of the Commission thereunder and (ii) nothing has come to the attention of such counsel that causes such
counsel to believe that (A) the Time of Sale Memorandum (except for the financial statements and financial schedules and other financial data, as to which such counsel need not express any belief) as of the date of the Purchase Agreement or as
amended or supplemented, if applicable, as of the date such opinion is delivered contained or contains any untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading or (B) the Final Memorandum (except for the financial statements and financial schedules and other financial data, as to which such counsel need not express any belief) when
issued contained, or as of the date such opinion is delivered contains, any untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. 
 With respect to the matters referred to in the paragraph above, counsel may state that
his opinions and beliefs are based upon his or her participation in the preparation of the Time of Sale Memorandum and the Final Memorandum (and any amendments or supplements thereto) and review and discussion of the contents thereof and review of
the documents incorporated by reference therein, but are without independent check or verification except as specified. 

  
 B-2

 EXHIBIT C 
 [FORM OF LOCK-UP LETTER] 

                   
 , 20     
 Stifel, Nicolaus & Company, Incorporated 

On behalf of itself and the several Initial Purchasers 
 c/o Stifel, Nicolaus & Company, Incorporated 
       390
Park Avenue, 2nd Floor New York, 
       New York 10022 
 Ladies and Gentlemen: 
 The undersigned understands that Stifel,
Nicolaus & Company, Incorporated (“Stifel”) proposes to enter into a Purchase Agreement (the “Purchase Agreement”) with Sunrise Senior Living, Inc., a Delaware corporation (the “Company”),
providing for the offering (the “Offering”) by the several Initial Purchasers, including Stifel (the “Initial Purchasers”), of $75,000,000 principal amount of Junior Subordinated Convertible Notes due 2041 of the
Company (the “Securities”). The Securities will be convertible into shares of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”). 

To induce the Initial Purchasers that may participate in the Offering to continue their efforts in connection with the Offering, the
undersigned hereby agrees that, without the prior written consent of Stifel on behalf of the Initial Purchasers, it will not, during the period commencing on the date hereof and ending 90 days after the date of the final offering memorandum relating
to the Offering (the “Final Memorandum”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), by the undersigned
or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of
the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to
(a) transactions relating to shares of Common Stock or other securities acquired in open market transactions after the 

  
 C-1

 
completion of the Offering, provided that no filing under Section 16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of
Common Stock or other securities acquired in such open market transactions, or (b) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock, provided that such plan
does not provide for the transfer of Common Stock during the 90-day restricted period and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of
the undersigned or the Company. In addition, the undersigned agrees that, without the prior written consent of Stifel on behalf of the Initial Purchasers, it will not, during the period commencing on the date hereof and ending 90 days after the date
of the Final Memorandum, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and
consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions.1 

The undersigned understands that the Company and the Initial Purchasers are relying upon this agreement in proceeding toward consummation
of the Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns. 

Whether or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering will only be made
pursuant to a Purchase Agreement, the terms of which are subject to negotiation between the Company and the Initial Purchasers. 
  

			
	Very truly yours,
		
		 	 
	(Name)
	
	 
	(Address)

  

 

1 The lock-up agreement of Paul Klaasen, Non-Executive Chair of the Company, will also contain the following paragraph:

 Notwithstanding the foregoing, transfers or sales of Common Stock pursuant to a 10b5-1 plan entered into by the undersigned
on March 3, 2011 are permitted during the 90-day restricted period. 

  
 C-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]